179 related articles for article (PubMed ID: 38131256)
1. Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction.
Li W; Wang Z; Hua C; Zhang H; Liu X; Zheng S; Lv Q; Jiang C; Dong J; Ma C; Du X
ESC Heart Fail; 2024 Apr; 11(2):709-718. PubMed ID: 38131256
[TBL] [Abstract][Full Text] [Related]
2. Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial.
Pandey A; Berry JD; Drazner MH; Fang JC; Tang WHW; Grodin JL
J Am Heart Assoc; 2018 Nov; 7(21):e009664. PubMed ID: 30376747
[TBL] [Abstract][Full Text] [Related]
3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
4. The frailty syndrome and outcomes in the TOPCAT trial.
Sanders NA; Supiano MA; Lewis EF; Liu J; Claggett B; Pfeffer MA; Desai AS; Sweitzer NK; Solomon SD; Fang JC
Eur J Heart Fail; 2018 Nov; 20(11):1570-1577. PubMed ID: 30225878
[TBL] [Abstract][Full Text] [Related]
5. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
6. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
[TBL] [Abstract][Full Text] [Related]
7. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
8. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
[TBL] [Abstract][Full Text] [Related]
10. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
[TBL] [Abstract][Full Text] [Related]
11. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
Grodin JL; Philips S; Mullens W; Nijst P; Martens P; Fang JC; Drazner MH; Tang WHW; Pandey A
Eur J Heart Fail; 2019 May; 21(5):634-642. PubMed ID: 30714658
[TBL] [Abstract][Full Text] [Related]
13. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
14. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
15. Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction.
Segar MW; Patel RB; Patel KV; Fudim M; DeVore AD; Martens P; Hedayati SS; Grodin JL; Tang WHW; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):68-77. PubMed ID: 33206129
[TBL] [Abstract][Full Text] [Related]
16. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
17. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Depressive Symptoms for Cardiovascular Events in Female Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction.
Zhao H; Jiang J; Zhong G; Peng Y; Wen Y; Liang Y; Shan Z
J Am Heart Assoc; 2024 May; 13(9):e032961. PubMed ID: 38686893
[TBL] [Abstract][Full Text] [Related]
19. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
[TBL] [Abstract][Full Text] [Related]
20. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
